Protagenic Therapeutics, Inc.\new

Protagenic Therapeutics, Inc. has entered into a material definitive agreement by issuing a $250,000 promissory note to Patness LLC. The note accrues simple interest at 1.0% per annum and is due within 180 days or upon the closing of an equity capital raise of at least $1,000,000. The company retains the option to prepay the note without penalty. The issuance was made in reliance on an exemption from registration under the Securities Act of 1933.

Protagenic Therapeutics, Inc. announced that its Chief Financial Officer, Alexander Arrow, MD, will be terminated effective April 30, 2026. The departure of a key executive can create uncertainty and potentially impact investor confidence.